Prognostic Significance of
DNA methylation
Schlaffen11
high-grade serous ovarian cancer
liquid biopsy
methylation specific PCR
plasma cell-free DNA
prognostic biomarker
progression free survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Dec 2021
21 Dec 2021
Historique:
received:
05
11
2021
revised:
08
12
2021
accepted:
16
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
Epigenetic alterations in ctDNA are highly promising as a source of novel potential liquid biopsy biomarkers and comprise a very promising liquid biopsy approach in ovarian cancer, for early diagnosis, prognosis and response to treatment. In the present study, we examined the methylation status of six gene promoters ( We report for the first time that the DNA methylation of Our results strongly indicate that
Sections du résumé
BACKGROUND
BACKGROUND
Epigenetic alterations in ctDNA are highly promising as a source of novel potential liquid biopsy biomarkers and comprise a very promising liquid biopsy approach in ovarian cancer, for early diagnosis, prognosis and response to treatment.
METHODS
METHODS
In the present study, we examined the methylation status of six gene promoters (
RESULTS
RESULTS
We report for the first time that the DNA methylation of
CONCLUSIONS
CONCLUSIONS
Our results strongly indicate that
Identifiants
pubmed: 35008168
pii: cancers14010004
doi: 10.3390/cancers14010004
pmc: PMC8750111
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : the European Union and Greek National funds through the Operational Program Competitive-ness, Entrepreneurship and Innovation, under the call RESEARCH - CREATE - INNOVATE
ID : T1RCI-02935
Références
Cancer Res. 1999 Feb 15;59(4):793-7
pubmed: 10029064
Br J Cancer. 2014 Apr 15;110(8):2054-62
pubmed: 24642624
N Engl J Med. 2000 Nov 9;343(19):1350-4
pubmed: 11070098
Gynecol Oncol. 2018 Aug;150(2):355-360
pubmed: 29807696
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
JCI Insight. 2021 Sep 22;6(18):
pubmed: 34549724
Front Cell Dev Biol. 2019 Sep 19;7:182
pubmed: 31608277
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
J Obstet Gynaecol Res. 2013 Feb;39(2):549-54
pubmed: 23006047
Cancer Treat Rev. 2020 Dec;91:102111
pubmed: 33068886
FEBS Lett. 2014 Aug 19;588(16):2671-84
pubmed: 24607545
J Natl Cancer Inst. 2000 Apr 5;92(7):564-9
pubmed: 10749912
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Clin Chem. 2013 Jan;59(1):270-9
pubmed: 23136251
Nat Rev Genet. 2016 May;17(5):284-99
pubmed: 26972587
Cancers (Basel). 2021 Sep 14;13(18):
pubmed: 34572834
Cancer Discov. 2021 Apr;11(4):858-873
pubmed: 33811121
Ann Oncol. 2017 Nov 1;28(suppl_8):viii1-viii7
pubmed: 29232467
Oncotarget. 2017 Mar 28;8(13):21429-21443
pubmed: 28206954
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Mol Oncol. 2021 Dec;15(12):3615-3625
pubmed: 34601813
Genomics. 2015 Dec;106(6):311-21
pubmed: 26363302
Expert Rev Mol Med. 2018 Dec 18;20:e6
pubmed: 30558693
Int J Cancer. 2009 Jan 15;124(2):387-93
pubmed: 18942711
Clin Cancer Res. 2017 Dec 1;23(23):7165-7170
pubmed: 28751443
J Natl Cancer Inst. 2020 Dec 14;112(12):1190-1203
pubmed: 32413141
N Engl J Med. 2008 Mar 13;358(11):1148-59
pubmed: 18337604
Clin Cancer Res. 2018 Sep 1;24(17):4066-4071
pubmed: 29650751
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Obstet Gynaecol Res. 2011 Jul;37(7):851-60
pubmed: 21450028
Int J Mol Sci. 2018 May 24;19(6):
pubmed: 29882921
Cancers (Basel). 2021 Apr 14;13(8):
pubmed: 33919854
Oncotarget. 2017 Jun 27;8(42):72054-72068
pubmed: 29069768
Drug Des Devel Ther. 2018 Mar 21;12:605-617
pubmed: 29606854
Oncotarget. 2017 Sep 15;8(47):83063-83074
pubmed: 29137324
Endocr Relat Cancer. 2016 Mar;23(3):R157-71
pubmed: 26764421
Lancet Oncol. 2015 Aug;16(8):928-36
pubmed: 26115797
Best Pract Res Clin Obstet Gynaecol. 2021 Sep 16;:
pubmed: 34607745
Int J Gynecol Cancer. 2018 Oct;28(8):1514-1519
pubmed: 30045136
Ann Pharmacother. 2020 Oct;54(10):1010-1015
pubmed: 32172572
Gynecol Oncol. 2012 Mar;124(3):582-8
pubmed: 22115852
Cancers (Basel). 2016 Feb 25;8(3):
pubmed: 26927176
Ann Oncol. 2019 Mar 1;30(3):374-384
pubmed: 30753271
Clin Chem. 2011 Aug;57(8):1169-77
pubmed: 21700955
N Engl J Med. 2018 Nov 01;379(18):1754-1765
pubmed: 30380390
Lancet. 2018 Sep 1;392(10149):777-786
pubmed: 30100054
Clin Biochem. 2013 Feb;46(3):235-40
pubmed: 23006792
Clin Epigenetics. 2018 Jul 26;10(1):99
pubmed: 30049288
Clin Cancer Res. 2018 Mar 15;24(6):1500-1510
pubmed: 29284708
Mol Oncol. 2021 Jun;15(6):1683-1700
pubmed: 33942482
Genome Med. 2017 Dec 22;9(1):116
pubmed: 29268796
Mol Cell. 2018 Feb 1;69(3):371-384.e6
pubmed: 29395061
Epigenomics. 2014 Jun;6(3):311-27
pubmed: 25111485
Mol Genet Genomic Med. 2018 Jan;6(1):69-76
pubmed: 29195029
Exp Hematol. 2019 Apr;72:1-8
pubmed: 30639577
PLoS One. 2019 Nov 4;14(11):e0224267
pubmed: 31682620
Mol Clin Oncol. 2019 Mar;10(3):323-330
pubmed: 30847169
Genes Chromosomes Cancer. 2019 Apr;58(4):219-232
pubmed: 30382599
Oncotarget. 2016 Jan 19;7(3):3084-97
pubmed: 26625211
Epigenomics. 2018 Nov;10(11):1397-1413
pubmed: 30324802